Patent ID: 11931358
Assignee: AMGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating a subject with heart failure (HF), comprising:
a. administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period of at least about 2 weeks,
b. subsequently administering to the subject a dose of the CSA for a second time period based on the subject's plasma concentration of the CSA,
wherein when the subject's plasma concentration of the CSA is less than a threshold concentration of 300 ng/mL, the dose that is subsequently administered to the subject is greater than the initial dose;
wherein the CSA is omecamtiv mecarbil, or a pharmaceutically acceptable salt thereof; and wherein the dose that is subsequently administered to the subject is about 50 mg twice daily, about 37.5 mg twice daily, or about 25 mg twice daily.